Xlife Sciences AG Unveils NeuroMex for Early Alzheimer’s Detection

Xlife Sciences AG, along with saniva diagnostics GmbH, has announced the development of NeuroMex, a groundbreaking medical device for early Alzheimer’s detection. This device, certified by the FDA and MDR, records motor responsiveness to detect Alzheimer's with 83.5% accuracy, bypassing traditional cognitive tests. Such innovation enables rapid, scalable screening and positions NeuroMex as a potential standard in annual health exams.

NeuroMex's entry into the partnering phase is set to open significant revenue opportunities and partnerships within healthcare. Leaders from Xlife Sciences and saniva diagnostics highlight the device's role in transforming early detection and timely healthcare interventions, placing Xlife Sciences at the forefront of the neurodegenerative diagnostics market.